Fig. 2

Survival plots of Immunity Score in different patient groups identified by proliferation and ER status in the AFFY1951 training dataset, two test datasets METABRIC and TARGETSEQ. Immunity Score demonstrated strongest outcome prediction in patients who were ER-negative and proliferation high in AFFY1951 (A) (p < 0.0001, n = 467), METABRIC (C) (p = 0.00018, n = 398) and TARGETSEQ (E) (p = 0.044, n = 65), but was insignificant in ER-positive and proliferation high patients in AFFY1951 (B) (p = 0.079, n = 585), METABRIC (D) (p = 0.22, n = 603) and TARGETSEQ (F) (p = 0.46, n = 97). High proliferation groups had proliferation scores no less than 50 and low proliferation groups had proliferation scores less than 50. Survival analysis of ER-negative or ER-positive and low proliferation patients were demonstrated in Supplementary Figure 1